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Abstract
Breast cancer is the major cause of cancer death in women worldwide. The most common
site of metastasis is bone. Bone metastases obstruct the normal bone remodeling process
and aberrantly enhance osteoclast-mediated bone resorption, which results in osteolytic le-
sions. 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is an endogenous ligand of peroxisome
proliferator-activated receptor gamma (PPARγ) that has anti-inflammatory and antitumor
activity at micromolar concentrations through PPARγ-dependent and/or PPARγ-indepen-
dent pathways. We investigated the inhibitory activity of 15d-PGJ2 on the bone loss that is
associated with breast cancer bone metastasis and estrogen deficiency caused by cancer
treatment. 15d-PGJ2 dose-dependently inhibited viability, migration, invasion, and parathy-
roid hormone-related protein (PTHrP) production in MDA-MB-231 breast cancer cells. 15d-
PGJ2 suppressed receptor activator of nuclear factor kappa-B ligand (RANKL) mRNA levels
and normalized osteoprotegerin (OPG) mRNA levels in hFOB1.19 osteoblastic cells treated
with culture medium from MDA-MB-231 cells or PTHrP, which decreased the RANKL/OPG
ratio. 15d-PGJ2 blocked RANKL-induced osteoclastogenesis and inhibited the formation of
resorption pits by decreasing the activities of cathepsin K and matrix metalloproteinases,
which are secreted by mature osteoclasts. 15d-PGJ2 exerted its effects on breast cancer
and bone cells via PPARγ-independent pathways. In Balb/c nu/numice that received an in-
tracardiac injection of MDA-MB-231 cells, subcutaneously injected 15d-PGJ2 substantially
decreased metastatic progression, cancer cell-mediated bone destruction in femora, tibiae,
and mandibles, and serum PTHrP levels. 15d-PGJ2 prevented the destruction of femoral
trabecular structures in estrogen-deprived ICR mice as measured by bone morphometric
parameters and serum biochemical data. Therefore, 15d-PGJ2 may be beneficial for the
prevention and treatment of breast cancer-associated bone diseases.
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Introduction
Breast cancer is inextricably linked to two bone diseases, bone metastasis and osteoporosis.
Metastatic breast cancer cells in the bone microenvironment disturb the balance between oste-
oclasts and osteoblasts, which disrupts the bone remodeling cycle and results in bone destruc-
tion [1]. Therefore, a “vicious cycle” between tumor cells and the bone microenvironment
plays a critical role in breast cancer-mediated bone loss [2–3]. Four essential contributors to
this vicious cycle are tumor cells, osteoblasts, osteoclasts, and resorbed bone matrix. Tumor
cells produce osteolytic factors, including parathyroid hormone-related protein (PTHrP) and
several interleukins [4]. These factors stimulate the expression of receptor activator of nuclear
factor-kappaB (RANK) ligand (RANKL) and inhibit the production of osteoprotegerin (OPG),
which is a decoy receptor of RANKL, in osteoblastic/stromal cells. RANKL triggers osteoclast
differentiation via binding to RANK on osteoclast precursors [5]. Bone resorption by mature
osteoclasts releases calcium and growth factors, such as transforming growth factor-beta
(TGF-β) and insulin-like growth factor-1, from the bone matrix. These growth factors further
stimulate tumor growth and the secretion ofosteolytic factors from tumor cells, which causes
severe osteolytic lesions [3,6]. In addition to the direct harm of bone metastasis, cancer therapy
for early stage and/or estrogen receptor-positive breast cancer, including cytotoxic chemother-
apy, induces premature ovarian failure and hormone deprivation therapy, which ultimately in-
creases the risk of bone loss because of estrogen deficiency [7]. Therefore, the maintenance and
restoration of bone health is particularly important to promote the efficacy of cancer treatment
and the quality of life in breast cancer patients.
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is one of the terminal products of the cycloox-
ygenase-mediated arachidonic acid pathway, and it is an endogenous ligand of peroxisome
proliferator-activated receptor gamma (PPARγ) [8]. Its cyclopentenone structure forms a cova-
lent adduct with cysteine residues in protein targets, which contributes to its anti-inflammatory
activity at micromolar concentrations [9]. Unlike pro-inflammatory prostaglandins, 15d-PGJ2
suppresses proliferation and induces apoptosis in different cancer cells [10–16]. 15d-PGJ2 in-
hibited the invasive capacities of MDA-MB-231 human breast cancer cells via by upregulating
a tissue inhibitor of matrix metalloproteinase-1 and decreasing gelatinase activity in condi-
tioned media [17]. However, 15d-PGJ2 increased the expression of matrix metalloproteinase
(MMP)-1 and vascular endothelial growth factor to induce angiogenesis in MCF-7 breast can-
cer cells [18,19]. PPARγ activation by rosiglitazone induced bone loss by reducing osteoblast
differentiation and activating osteoclast differentiation [20]. However, a recent study showed
that rosiglitazone inhibited TNF-α-induced osteoclast differentiation and bone resorption
[21]. Several studies also demonstrated the inhibitory effect of PPARγ agonists, including 15d-
PGJ2, ciglitazone, and troglitazone, on osteoclast formation [22–24].
This study determined the inhibitory activity of 15d-PGJ2 on cancer-associated bone dis-
eases. We examined the effect of 15d-PGJ2 on the viability, migration, invasion, and secretion
of PTHrP in MDA-MB-231 metastatic human breast cancer cells, RANKL and OPG expres-
sion in hFOB1.19 osteoblastic cells, RANKL-induced osteoclastogenesis in mouse bone mar-
row macrophages, and bone resorption by mature osteoclasts. We further evaluated the effect
of 15d-PGJ2 on bone loss in mice that received an intracardiac inoculation of human metastatic
breast cancer cells and ovariectomized mice, which reflected estrogen deficiency.
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Materials and Methods
Materials
15d-PGJ2 and the PPARγ antagonist GW9662 were purchased from Cayman Chemicals (Ann
Arbor, MI), dissolved in dimethyl sulfoxide (DMSO), and diluted with culture media immedi-
ately prior to use. Dulbecco’s modified Eagle’s medium (DMEM), minimum essential medi-
um-alpha (α-MEM), DMEM:nutrient mixture F-12 (DMEM/F-12) without phenol red,
Dulbecco’s phosphate-buffered saline (PBS), Hanks’ balanced salt solution (HBSS), fetal bovine
serum (FBS), an antibiotic-antimycotic mixture (100 U/ml penicillin and 100 μg/ml streptomy-
cin), 0.25% trypsin-EDTA, and Geneticin (G-418) were products of Gibco-BRL (Grand Island,
NY). Recombinant mouse soluble RANKL and murine macrophage-colony stimulating factor
(M-CSF) were obtained from Koma Biotech (Seoul, South Korea) and R&D Systems (Minne-
apolis, MN), respectively. Zoledronic acid (di-sodium salt) was purchased from Enzo Life Sci-
ences (Farmingdale, NY) and D-luciferin potassium salt was obtained from Goldbio
Technology (St. Louis, MO). Histopaque-1083, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT), 17β-estradiol (E2), and DMSO were obtained from Sigma-Aldrich
(St. Louis, MO). All reagents used in this study were of analytical grade.
Cell culture
MDA-MB-231 human mammary carcinoma cells (Korean Cell Line Bank, Seoul, South Korea)
were cultured in DMEM supplemented with 10% FBS and a 1% antibiotic-antimycotic mixture
at 37°C under a humidified atmosphere of 5% CO2. Human fetal osteoblastic hFOB1.19 cells
(American Type Culture Collection, Manassas, VA) were grown in DMEM/F-12 without phe-
nol red, containing 10% FBS, 1% antibiotic-antimycotic mixture, and 0.3 mg/ml G418 at 34°C
in 5% CO2 in a humidified incubator. Mouse bone marrow macrophages (BMMs) were isolat-
ed from the tibiae of male ICR mice using histopaque density gradient centrifugation as de-
scribed previously [6] and cultured in α-MEM containing 10% FBS, 1% antibiotic-antimycotic
mixture, and 30 ng/ml M-CSF at 37°C in a humidified atmosphere of 5% CO2.
Animals
Male ICR mice (3 weeks old, 20 ± 3 g), female Balb/c nu/numice (5 weeks old, 20 ± 3 g), and
female sham-operated and ovariectomized (OVX) ICR mice (8–9 weeks old, 28 ± 2 g) were ob-
tained from Central Lab Animal (Seoul, South Korea). The mice were provided free access to a
standard chow diet (Orient, Seongnam, Korea) and tap water ad libitum and housed under spe-
cific pathogen-free conditions with a 12-h light/dark cycle and a relative humidity of 50 ± 5%
at 22 ± 2°C. The Institutional Animal Care and Use Committee of Department of Laboratory
Animal Resources, Yonsei Biomedical Research Institute, Yonsei University College of Medi-
cine approved all animal experiments.
Luciferase vector construction and transfection
The firefly luciferase gene from Photinus pyralis was amplified using polymerase chain reaction
(PCR)-based methods and a pTAL-Luc vector (Clontech Laboratories, Palo Alto, CA) followed
by subcloning into the pLenti6/V5 Directional TOPO cloning vector in the ViraPower Lenti-
viral Expression System (Invitrogen, Carlsbad, CA) to generate lentiviral particles with lenti-
viral vector-based luciferase. The pLenti6/V5-Luc plasmid was subjected to DNA sequencing
analysis to confirm successful construction. Lentivirus particles were produced using cotrans-
fection of the 293FT producer cell line with the pLenti6/V5-Luc plasmid and ViraPower Pack-
aging Mix. Cells were transduced using 2 x 107 lentiviral particles in the transduction enhancer
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Polybrene at 10 μg/ml to establish luciferase-transfected MDA-MB-231 stable cells
(MDA-MD-231/Luc+). Blasticidin (10 μg/ml) was added to select stably transduced cells. Blas-
ticidin-resistant clones exhibited V5 epitope detection against an anti-V5 antibody on Western
blot analysis and revealed the maximum level of luciferase activity in a microplate spectrofluo-
rometer (Molecular Devices, Palo Alto, CA).
Cell viability assay
MDA-MB-231 cells (1 x 104 cells/well) were seeded into a 96-well plate with 10% FBS-DMEM.
The cells were incubated in serum-free media with various concentrations of 15d-PGJ2 for 24
or 72 h. hFOB1.19 human osteoblastic cells (1x 104 cells/well) were incubated in serum-free
media with the indicated concentrations of 15d-PGJ2 for 6 h or 24 h. BMMs (5 x 10
4 cells/well)
were cultured in media with the indicated concentrations of 15d-PGJ2 in the presence of 10%
FBS and 30 ng/ml M-CSF for 5 days. Cell viability was determined using the MTT assay as de-
scribed previously [6].
Cell migration assay
MDA-MB-231 cells were seeded in a 6-well plate and allowed to grow to 90% confluency. One
artificial wound per well was scratched into monolayers using the narrow end of a sterile mi-
cropipette tip, and the wounded areas were photographed. Cells were incubated in serum-free
DMEM with mitomycin (5 μg/ml) and various concentrations of 15d-PGJ2. The scratched
areas were photographed again 40 h later at the identical location of the initial image. The
width of the wounded cell monolayer was measured using ImageJ software, and the percentage
of wound closure was derived using the following formula: (1–(current wound width/initial
wound width)) × 100.
Transwell invasion assay
A cell invasion assay was performed using a Transwell chamber (Corning, Cambridge, MA)
that contained a polycarbonate membrane filter (6.5 mm diameter, 8 μm pore size). The bot-
tom of the filter was coated with 0.1% (w/v) gelatin. Matrigel (BD Biosciences, San Jose, CA),
which is a mixture of basement membrane extracellular matrix proteins, was diluted with
DMEM to a final concentration of 1 mg/ml and applied to coat the membrane filter.
MDA-MB-231 cell suspensions (2 x 104 cells/100 μl) with various concentrations of 15d-PGJ2
were added to the inserts of each coated Transwell. The lower chamber contained 600 μl of
media with 1% FBS and 15d-PGJ2. Transwell chambers were incubated for 24 h at 37°C. Cells
were fixed with 70% methanol, and the membranes were stained with hematoxylin. Non-in-
vading cells on the upper surface of the membrane were scraped with cotton swabs, and invad-
ing cells that remained on the bottom surface were mounted on slides. Four random fields for
each membrane were captured, and cells in the captured fields were quantified under a Zeiss
AXio imager microscope (Carl Zeiss AG, Göttingen, Germany).
PTHrP assay
MDA-MB-231 cells were seeded at a density of 1 x 105 cells into a 96-well plate and incubated
to adhere overnight. Cells were treated with the indicated concentrations of 15d-PGJ2, TGF-β,
and/or GW9662 for 24 h. The plate was centrifuged, and media were collected. PTHrP levels in
the collected culture media were quantified using a human PTHrP enzyme-linked immunosor-
bent assay (ELISA) kit (USCN Life Science, Wuhan, China) [25].
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Western blot analysis
MDA-MB-231 cells were seeded at 1 x 106 cells in 100 mm cell culture dishes and incubated
with the indicated concentrations of TGF-β, 15d-PGJ2, and/or GW9662 for 24 h. Cells were
lysed in RIPA buffer (Cell Signaling Technology, Danvers, MA) containing 1 mM phenyl-
methylsulfonyl fluoride and protease inhibitor cocktail tablets (Roche Diagnostics) or the nu-
clear/cytosol fractionation kit (BioVision, Mountain View, CA). Samples were centrifuged, and
proteins in the supernatants were quantitated using BCA protein assay reagents (Pierce Bio-
technology, Rockford, IL). Proteins were separated using 12% sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes
(Millipore, Danvers, MA). Membranes were blocked for 1 h in 5% skim milk and incubated
with rabbit anti-Smad2, rabbit anti-phosphorylated Smad2 (Cell Signaling Technology), rabbit
anti-β -actin (Sigma-Aldrich), and mouse anti-Lamin B (Invitrogen) at 4°C overnight, followed
by incubation with horseradish peroxidase-conjugated secondary antibody for 1 h at room
temperature. Proteins were visualized using an enhanced chemiluminescence kit (GE Health-
care, Buckinghamshire, UK).
Quantitative real-time PCR
The medium was replaced with serum-free DMEM/F-12 when seeded MDA-MB-231 cells
reached 70–80% confluency in 10% FBS-DMEM. Conditioned media (CM), including
MDA-MB-231 cell-secreted osteolytic factors, were collected after a 24-h incubation. Osteo-
blastic hFOB1.19 cells (1 x 106 cells/100 mm culture dish) were treated with the indicated con-
centrations of 15d-PGJ2 and/or GW9662 in DMEM with 75% CM or PTHrP (100 nM) for 6 h.
Total RNA was isolated using an RNeasy Mini Kit (Qiagen, Valencia, CA). First-strand cDNA
from 1 μg total RNA was synthesized using the PrimeScript RT reagent kit (TaKaRa, Dalian,
China). Real-time quantitative RT-PCR was performed using the 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA) and the SYBR Premix Ex Taq (TaKaRa) in a 96-well op-
tical reaction plate according to the manufacturer’s instructions. The following PCR conditions
were used: initial denaturation at 95°C for 30 s, followed by 40 cycles of denaturation at 95°C
for 5 s and annealing at 60°C for 31 s. Cycle threshold (Ct) values were established. Relative
gene expressions of RANKL and OPG to the reference gene GAPDH were determined using
the 2−ΔΔCt method. The following primer sequences were used: RANKL, forward 5’-ATGGTG
GATGGCTCATGGTTAG-3’ and reverse 5’-GAGCAAAAGGCTGAGCTTCAAG-3’; OPG,
forward 50-CCAGTGACCAGATCCTGAAGCT-30 and reverse 50-GGTGTCTTGGT
CGCCATTTT-30; and GAPDH, forward 50-AGTCCTTCCACGATACCAAAGT-30 and
reverse 50-CATGAGAAGTATGACAACAGCCT-30.
Osteoclast formation assay
BMMs (5 x 104 cells/well) were seeded into a 96-well plate and cultured in α-MEM with 10%
FBS, 30 ng/ml M-CSF and the indicated concentrations of 15d-PGJ2 in the absence or presence
of 100 ng/ml RANKL. Cells were cultured for 5 days, and fresh media containing the appropri-
ate chemicals was replaced every other day. Cells were fixed using 3.7% (v/v) formaldehyde
and stained for tartrate-resistant acid phosphatase (TRAP) activity for 10 min at 37°C using
the Acid Phosphatase Leukocyte kit (Sigma-Aldrich) as described previously [6,26]. TRAP-
positive multinucleated cells (MNCs) with more than three nuclei were quantified as differenti-
ated osteoclasts using an Olympus IX70 inverted microscope (Olympus Optical, Tokyo, Japan)
(100x magnification).
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Pit formation assay
BMMs (5 x 104 cells/well) were plated onto BD BioCoat Osteologic MultiTest Slides with min-
eralized calcium phosphate thin films (BD Biosciences) and cultured in α-MEM containing
10% FBS, 30 ng/ml M-CSF, and 100 ng/ml RANKL for 4 days as described previously [26]. Dif-
ferentiated osteoclasts were treated with 15d-PGJ2 at the indicated concentrations for an addi-
tional 10 days. Media were replaced every other day. Media were collected to measure
cathepsin K and MMP activity, and cells were treated with 4% sodium hypochlorite. Slides
were washed twice using distilled water, and resorbed pits were observed under a light micro-
scope (100x magnification).
Cathepsin K activity assay and gelatin zymography
The activity of cathepsin K and MMPs in the collected media was measured using a SensiZyme
Cathepsin K Activity Assay Kit (Sigma-Aldrich) and gelatin zymography as described previ-
ously [26]. Cathepsin K activity was calculated using a standard curve and the gelatinolytic ac-
tivities of MMPs were detected as clear bands against a dark blue background.
Animal model of breast cancer bone metastasis
MDA-MB-231/Luc+ cells (1 x 106 cells/0.1 ml in HBSS) were injected into the left cardiac ven-
tricle of female Balb/c nu/numice as previously described [27,28]. Animals were divided into
four groups of 10 mice on the following day and subcutaneously administered vehicle (PBS
containing 2% DMSO) alone, 0.5 or 2 mg/kg 15d-PGJ2, or 0.1 mg/kg zoledronic acid as a posi-
tive control, three times per week for six weeks. Metastatic progression in nude mice was visu-
alized using bioluminescence imaging three and five weeks after intracardiac injections. Mice
were anesthetized for imaging using a Xenogen XGI-8 Gas Anesthesia System and injected
intraperitoneally with 150 mg/kg of D-luciferin potassium salt in PBS. The luciferase activity
was visualized using an intensified CCD video camera connected to the in vivo IVIS Imaging
System 200 Series (Caliper Life Sciences, Hopkinton, MA). Bioluminescence from mice was ex-
pressed as total photon flux measured in photons/sec/cm2 per steradian (sr) using Xenogen
Living Image software. Blood was collected by intracardiac puncture at the end of the experi-
ment for the serum PTHrP assay. The femora, tibiae, and mandibles of nude mice were also
collected for μCT analysis.
Amurine model of ovariectomy-induced bone loss
OVXmice were divided into four groups of 10 mice, and subcutaneously administered vehicle
(PBS containing 2% DMSO), 0.5 or 2 mg/kg 15d-PGJ2, or 10 μg/kg E2 as a positive control,
three times per week for 10 weeks. Sham-operated mice were treated with vehicle alone. Body
weights were measured weekly using an electronic scale. Blood samples were collected by cardi-
ac puncture at the end of the experimental period, and the femora were dissected.
μCT analysis
The femora, tibiae, and mandibles of nude mice and the femora of sham-operated and OVX
mice were examined using a SkyScan 1076 μCT scanner (SkyScan, Aartselaar, Belgium) with
100 kV, 140 μA current, rotation step 0.6°, and camera pixel size of 35 μm as described previ-
ously [6,26]. Three-dimensional (3D) images were reconstructed based on the μCT images
using SkyScan NRecon software and analyzed using SkyScan's computed tomography analyzer
software (CTAn). The following parameters were analyzed in the proximal tibiae of nude mice
and the distal femora of sham-operated and OVX mice for quantitative analyses of bone
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histomorphometry: percent bone volume (BV/TV, %), trabecular thickness (Tb.Th, mm), tra-
becular number (Tb.N, mm-1), trabecular separation (Tb.Sp, mm), and structure model index
(SMI). Values for bone mineral density (BMD) were measured in the femora of sham-operated
and OVX mice.
Determination of biochemical bone parameters
The collected blood samples were allowed to clot for 2 h at room temperature and centrifuged
at 2,000 ×g for 20 min to obtain sera as described previously [6,26]. Serum PTHrP levels from
10 nude mice were quantified in triplicate using a specific PTHrP ELISA kit. Calcium and alka-
line phosphatase (ALP) levels in the sera of sham-operated and OVX mice were determined
using QuantiChrome calcium and ALP assay kits (BioAssay Systems, Hayward, CA), respec-
tively. TRAP and C-terminal telopeptides of type I collagen (CTX) levels were measured using
mouse TRAP and RatLaps enzyme immunoassay (EIA) kits (Immunodiagnostic Systems,
Fountain Hills, AZ), respectively. Serum levels of osteocalcin were detected using a mouse
osteocalcin EIA kit (Biomedical Technologies, Stoughton, MA), and tumor necrosis factor-
alpha (TNF-α) and interleukin-1 beta (IL-1β) levels were quantified using respective commer-
cially available ELISA kits (R&D Systems). The serum levels of these factors in 10 sham-operat-
ed and OVX mice were measured in duplicate.
Goldner's trichrome staining
Mouse femora were fixed in a 10% buffered formalin solution for 48 h, decalcified with a 10%
EDTA solution, and embedded in paraffin. Five-μm–thick serial sagittal sections were stained
using Goldner's trichrome according to the protocol specified by Electron Microscopy Sciences
(Hatfield, PA).
Statistical analysis
Data are expressed as the means ± standard error (SEM) and analyzed using one-way ANOVA
and Student’s t-test. A value of P< 0.05 was considered statistically significant.
Results
15d-PGJ2 reduced the viability, migration, and invasion of MDA-MB-231
breast cancer cells
The viability of MDA-MB-231 cells treated with the indicated concentrations of 15d-PGJ2 for
24 or 72 h was reduced in a dose-dependent manner (Fig 1A). Cells exposed to 3, 5, 10, and
30 μM concentrations of 15d-PGJ2 were viable to 91%, 65%, 54%, and 38%, respectively, after
24 h of treatment and 65%, 33%, 22%, and 8%, respectively, after 72 h of treatment. The scratch
wound healing assay showed that a 40 h treatment with 15d-PGJ2 at noncytotoxic concentra-
tions inhibited the migratory ability of MDA-MB-231 cells by 32% at 0.5 μM, 46% at 1 μM,
and 62% at 3 μM (Fig 1B). 15d-PGJ2 also decreased cell invasion in a dose-dependent manner.
The number of invaded cells was inhibited by 25%, 53%, and 73% following treatment for 24 h
with 15d-PGJ2 at concentrations of 0.5, 1, and 3 μM, respectively (Fig 1C).
15d-PGJ2 inhibited PTHrP production in MDA-MB-231 breast cancer
cells
We investigated the effect of 15d-PGJ2 on the secretion of PTHrP, which plays a central role in
the osteolytic bone metastasis of MDA-MB-231 cells [29]. PTHrP levels were decreased by
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24% in the culture media of MDA-MB-231 cells treated with 1 μM 15d-PGJ2 for 24 h and 39%
with 3 μM 15d-PGJ2 (Fig 2A). TGF-β stimulation elevated PTHrP levels in the culture media
by 1.6-fold, but treatment with 3 μM 15d-PGJ2 noticeably inhibited TGF-β-induced PTHrP
production in MDA-MB-231 cells. Treatment with GW9662, a PPAR-γ antagonist, did not
normalize the reduced PTHrP levels following 15d-PGJ2 treatment in MDA-MB-231 cells re-
gardless of TGF-β treatment (Fig 2B). 15d-PGJ2 treatment inhibited the substantial enhance-
ment in Smad2 phosphorylation and nuclear levels of pSmad2 in TGF-β -stimulated cells. The
inhibitory effect of 15d-PGJ2 on TGF-β -induced activation of Smad2 remained in the presence
of GW9662 (Fig 2C). These results demonstrate that 15d-PGJ2 inhibits PTHrP production
through a PPARγ-independent pathway in MDA-MB-231 breast cancer cells regardless of
TGF- stimulation.
15d-PGJ2 inhibited the RANKL/OPG ratio in hFOB1.19 osteoblastic
cells
15d-PGJ2 treatment at concentrations less than 5 μM for 6 h did not show cytotoxic effects, but
a 24-h treatment inhibited cell viability by 47% at 3 μM and 60% at 10 μM in hFOB1.19 human
osteoblastic cells (Fig 3A). Real-time PCR analysis indicated that RANKL mRNA levels in-
creased considerably and OPG mRNA levels decreased noticeably in osteoblastic hFOB1.19
Fig 1. Effect of 15d-PGJ2 on the viability, migration, and invasion of MDA-MB-231 cells. (A) Cells were
incubated in serum-free media containing various concentrations of 15d-PGJ2 for 24 or 72 h. Cell viability
was determined using the MTT assay. (B) Cells were grown to confluency in monolayers, scratched using a
micropipette tip, and treated with the indicated concentrations of 15d-PGJ2 for 40 h. Scratched areas on
cultured MDA-MB-231 cells were observed under a light microscope immediately and 40 h after scratching
(40x magnification). Relative migrating distances of cells into scratched areas were measured using ImageJ
software. Data are expressed as percentages of cell migrating distances at 40 h compared with 0 h. (C) Cells
were stimulated with a 1% FBS attractant and treated with 15d-PGJ2 at the indicated concentrations for 24 h.
Cells that traversed across the Matrigel matrix were stained with hematoxylin, and representative images
were visualized using light microscopy (200x magnification). The numbers of invaded cells were counted in
four random fields per membrane filter. Data are expressed as means ± SEM. *P<0.05, **P<0.001 vs.
untreated cells.
doi:10.1371/journal.pone.0122764.g001
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cells stimulated with 75% CM fromMDA-MB-231 breast cancer cells or PTHrP (100 nM) for
6 h, which elevated the RANKL/OPG ratio. However, treatment with 15d-PGJ2 dose-depen-
dently suppressed the CM- and PTHrP-induced increase in the RANKL/OPG ratio by blocking
increases in RANKL mRNA levels and decreases in OPG mRNA levels in hFOB1.19 cells ex-
posed to CM and PTHrP, respectively (Fig 3B). GW9662 treatment did not rescue RANKL and
OPG mRNA levels that were altered by 15d-PGJ2 treatment in CM and PTHrP-treated
hFOB1.19 cells. These results indicate that 15d-PGJ2 inhibits the RANKL/OPG ratio in
hFOB1.19 cells stimulated with MDA-MB-231 cell-derived osteolytic factors, particularly
PTHrP.
15d-PGJ2 inhibited RANKL-induced osteoclast differentiation and
activity
Treatment with 15d-PGJ2 for 5 days inhibited cell viability by 19% at a concentration of 3 μM,
36% at 5 μM, and 53% at 10 μM in BMMs. BMMs were differentiated to TRAP-positive multi-
nucleated cells as osteoclasts in the presence of M-CSF and RANKL for 5 days, but treatment
with 15d-PGJ2 inhibited RANKL-induced osteoclast formation in a dose-related manner.
Treatment with 0.5, 1, and 3 μM 15d-PGJ2 reduced the number of differentiated osteoclasts by
32%, 55%, and 93%, respectively. GW9662 treatment did not attenuate the inhibitory effect of
15d-PGJ2 on RANKL-induced osteoclast formation (Fig 4A). The formation of resorption pits
determined the activity of mature osteoclasts. Osteoclast differentiation was induced on calci-
um phosphate-coated plates, and cells were incubated with 15d-PGJ2 in the presence of M-CSF
and RANKL for 10 days. Treatment with 15d-PGJ2 dose-dependently suppressed the
Fig 2. Effect of 15d-PGJ2 on PTHrP production in MDA-MB-231 cells. The cells were treated with (A)
various concentrations of 15d-PGJ2 or (B) TGF-β, 15d-PGJ2 and/or GW9662 for 24 h. PTHrP levels were
measured in the cultured media of MDA-MB-231 cells using a commercial human PTHrP ELISA kit. Data are
expressed as the means ± SEM. *P<0.05, **P<0.01 vs. untreated cells. #P<0.01 vs. TGF-β -treated cells.
(C) The level of Smad2 in total lysates and nuclear and cytoplasmic fractions was determined using western
blotting in MDA-MB-231 cells stimulated by TGF- β, 15d-PGJ2 and/or GW9662 PPARγ antagonist for 24 h.
The cropped blots are representative of experiments that were repeated three times.
doi:10.1371/journal.pone.0122764.g002
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formation of resorbed areas (Fig 4B). RANKL treatment significantly increased the activity of
cathepsin K in cultured media, but 15d-PGJ2 treatment suppressed the activity almost to con-
trol levels (Fig 4C). Gelatin zymography indicated that the levels of pro- and active forms of
MMP-2 and MMP-9 were considerably enhanced in cultured media of RANKL-induced ma-
ture osteoclasts, but 15d-PGJ2 treatment decreased the levels of these MMPs in a dose-depen-
dent manner (Fig 4D).
15d-PGJ2 inhibited osteolytic bone metastasis by breast cancer cells in
nude mice
MDA-MB-231/Luc+ cells were inoculated into the left ventricles of nude mice to induce bone
metastasis of breast cancer cells, and 15d-PGJ2 or zoledronic acid was subcutaneously injected
for six weeks. Bioluminescence imaging showed that subcutaneous administration of 15d-PGJ2
or zoledronic acid for three and five weeks inhibited the metastatic progression of MDA-MB-
231/Luc+ cells (Fig 5A). Osteolytic lesions of all mice were analyzed using μCT six weeks after
cancer cell injections. Radiographic images of MDA-MB-231/Luc+ cell-injected mice indicated
that osteolytic lesions were substantially developed in mandibles, distal femora, and proximal
tibiae. However, 15d-PGJ2 or zoledronic acid administration inhibited cancer cell-induced
osteolytic lesions in a dose-dependent manner (Fig 5B). 3D-images also revealed that
MDA-MB-231/Luc+ cells induced severe destruction in the inner part of the mandible, but
treatment with 15d-PGJ2 or zoledronic acid noticeably reduced this damage (Fig 5C). Bone
morphometric analyses demonstrated that the injection of MDA-MB-231/Luc+ cells decreased
BV/TV, Tb.Th, and Tb.N and increased Tb.Sp and SMI, but treatment with 15d-PGJ2 or zole-
dronic acid induced a recovery of these bone morphometric parameters. Furthermore, the
Fig 3. Effect of 15d-PGJ2 on RANKL and OPGmRNA expression in hFOB1.19 human osteoblastic
cells. (A) hFOB1.19 cells were treated with the indicated concentrations of 15d-PGJ2 in DMEM/F12 for 6 h or
24 h. Cell viability was determined using the MTT assay. (B) hFOB1.19 cells were treated with the indicated
concentrations of 15d-PGJ2 in DMEM/F12 containing 75%CMof MDA-MB-231 cells or PTHrP (100 ng) for 6 h.
mRNA levels of RANKL and OPGwere analyzed using real time-PCR. Graphs are expressed as the ratio of the
densitometric intensity of RANKL to OPG after normalization to GAPDH. Data represent the means ± SEM.
*P<0.05, **P<0.001 vs. untreated cells, #P<0.05, ##P<0.001 vs. CM- or PTHrP-treated cells.
doi:10.1371/journal.pone.0122764.g003
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levels of PTHrP were significantly increased in the sera of mice that received an intracardiac in-
jection of MDA-MB-231/Luc+ cells, but treatment with 15d-PGJ2 or zoledronic acid inhibited
the increase in PTHrP levels (Fig 5D).
15d-PGJ2 inhibited ovariectomy-induced bone loss
Ovariectomy-induced osteoporosis is commonly used as an animal model of bone loss due to
estrogen deficiency in humans [30]. μCT analysis showed that BMD, BV/TV, Tb.Th and Tb.N
decreased, but Tb.Sp and SMI increased, in OVX mice compared to the sham group. However,
these bone morphometric parameters significantly recovered to control levels in 15d-PGJ2- or
E2-treated OVX mice (Fig 6A). 3D-images and Goldner’s trichrome staining of distal femoral
metaphyses revealed that the subcutaneous administration of 15d-PGJ2 or E2 in OVX mice
dose-dependently suppressed severe trabecular bone loss in OVX mice (Fig 6B). In addition,
treatment with 15d-PGJ2 or E2 blocked elevations in body weight in OVX mice. We measured
ALP activity and osteocalcin level as markers of bone formation and calcium, TRAP, and CTX
Fig 4. Effect of 15d-PGJ2 on RANKL-induced osteoclast differentiation and activation. (A) BMMs
isolated from ICR mice were treated with M-CSF (30 ng/ml), RANKL (100 ng/ml), 15d-PGJ2, and/or GW9662
for 5 days. TRAP staining was performed to detect osteoclast formation. TRAP-positive multinucleated cells
( 3 nuclei) as differentiated osteoclasts were observed (100x magnification) and counted under an inverted
microscope. (B) The differentiated BMMs were treated with 15d-PGJ2 in the presence of M-CSF (30 ng/ml)
and RANKL (100 ng/ml) for an additional 10 days. The formed resorption pits were visualized using light
microscopy (100x magnification). (C) The level of cathepsin K in the cultured media was measured using a
commercially available ELISA kit. (D) The activities of MMPs were determined using gelatin zymograpy as
clear bands against a blue background that corresponded to active MMP-2/9 (62/92 kDa) and pro-MMP-2/9
(72/105 kDa). The cropped gel image is representative of experiments that were repeated three times. Data
are expressed as the means ± SEM. *P<0.001 vs. RANKL-untreated cells. #P<0.05, ##P<0.001 vs. RANKL-
treated cells.
doi:10.1371/journal.pone.0122764.g004
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Fig 5. Effect of 15d-PGJ2 on osteolytic bonemetastasis in nudemice that received intracardiac
injections of MDA-MB-231 cells.MDA-MB-231/Luc+ cells were inoculated into the left ventricles of female
nude mice. 15d-PGJ2 or zoledronic acid (ZA) was subcutaneously injected 3 times per week for 6 weeks at
the indicated doses (n = 10). (A) Metastatic progression was detected by measuring bioluminescence in the
samemice at 3 and 5 weeks after the injection of cancer cells. The formed metastases were quantified by
measuring total photon flux per second. (B) Radiographic images of mandibles, distal femora, and proximal
tibiae were scanned using μCT 6 weeks after the injection of cancer cells. Arrowheads indicate osteolytic
lesions. (C) The mandibles of mice were analyzed using 3D-images. (D) Bone morphometric parameters,
including BV/TV, Tb.N, Tb.Th, Tb.Sp, and SMI, were measured using μCT analysis of the proximal tibiae
frommice. (E) Serum PTHrP levels were assayed using a commercially available ELISA kit. Data are
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were used as the markers of bone resorption. The serum levels of these bone turnover markers
were elevated significantly in OVX mice, but these levels noticeably decreased in 15d-PGJ2- or
E2-treated OVX mice (Fig 6C). Treatment with 15d-PGJ2 or E2 also significantly reduced
TNF-α and IL-1β levels in the sera of OVX mice (Fig 6D).
Discussion
The present study determined the inhibitory activity of 15d-PGJ2 on breast cancer-associated
bone diseases. We first investigated whether 15d-PGJ2 blocked breast cancer bone metastasis
and the resulting bone loss. We found that 15d-PGJ2 attenuated cell migration and the invasion
of MDA-MB-231 human breast cancer cells at noncytotoxic concentrations. Treatment with
15d-PGJ2 reduced the secreted levels of PTHrP through a PPARγ-independent pathway in
MDA-MB-231 cells regardless of TGF-β stimulation. Cancer cell-derived PTHrP attracted at-
tention as a key mediator of the triggering and intensification of the vicious cycle of osteolytic
bone metastasis in the bone microenvironment [31]. Among the bone matrix-derived growth
factors, TGF-β regulates PTHrP production via Smad-dependent or Smad-independent path-
ways [32–34]. Our data indicated that 15d-PGJ2 inhibited Smad2 phosphorylation regardless
of the PPARγ pathway, and consequently, reduced levels of pSmad2 were detected in the nucle-
us and cytoplasm. These results suggest that treatment with 15d-PGJ2 suppresses the metastatic
progression of MDA-MB-231 cells and decreases PTHrP production through a PPAR-inde-
pendent but Smad2-dependent pathway in MDA-MB-231 cells that primarily metastasized
into bone.
The majority of patients with breast cancer bone metastasis exhibit osteolytic lesions that
are accompanied by severe bone destruction. Osteolysis is caused by mature osteoclasts derived
from hematopoietic mononuclear precursors not a direct effect of cancer cells on bone [35]. Al-
most all of the other mediators that induce osteoclast differentiation and activation transduce
and amplify signals through RANKL, which is produced by osteoblastic stromal cells [5].
PTHrP also enhances osteoclastogenesis and the activity of mature osteoclasts via an up-regu-
lation of RANKL and down-regulation of its decoy receptor OPG in osteoblasts [36]. Noncyto-
toxic concentrations of 15d-PGJ2 significantly inhibited an increase in RANKL mRNA
expression and a decrease in OPG mRNA expression in hFOB1.19 human osteoblastic cells
stimulated with an MDA-MB-231 cell-derived conditioned medium or PTHrP in our study.
Osteoclasts that are differentiated by RANKL produce acidic conditions to dissolve calcium hy-
droxyapatite and secrete various proteolytic enzymes, such as cathepsin K and MMPs, to de-
grade organic components in the bone matrix, which releases bone-stored growth factors
[37,38]. Therefore, the inhibition of osteoclast-mediated bone resorption can ultimately con-
tribute to the prevention of additional tumor growth and cancer cell-mediated osteolysis. 15d-
PGJ2 reduced RANKL-induced osteoclast differentiation and inhibited the formation of osteo-
clast-mediated resorption pits by suppressing the proteolytic activities of cathepsin K and
MMP-2/9. Treatment with GW9662 did not affect the anti-osteoclastogenic activity of 15d-
PGJ2. These results indicate that 15d-PGJ2 blocks breast cancer-mediated bone destruction by
reducing the RANKL/OPG ratio in osteoblasts that are exposed to MDA-MB-231 cell-derived
osteolytic factors and inhibiting the formation and function of osteoclasts in RANKL-treated
osteoclast precursors in a PPAR-independent manner.
We further estimated the inhibitory activity of 15d-PGJ2 on osteolytic bone metastasis in
nude mice inoculated with MDA-MB-231/Luc+ cells into the left cardiac ventricle and
expressed as the means ± SEM. #P<0.05, ##P<0.01 vs. control group.*P<0.05, **P<0.01 vs. vehicle-
treated group inoculated with cancer cells.
doi:10.1371/journal.pone.0122764.g005
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subcutaneously injected with 15d-PGJ2 or zoledronic acid for six weeks. Metastatic progression
was delayed and osteolytic lesions in mandibles, femora, and tibiae were decreased in 15d-
PGJ2-treated mice, which was supported by bioluminescence imaging, radiographic and 3D
images, and bone morphometric parameters. Moreover, the reduced serum PTHrP levels in
MDA-MB-231cell-injected mice treated with15d-PGJ2 may be linked with the in vitro inhibito-
ry effect of 15d-PGJ2 on PTHrP production. Zoledronic acid used as a positive control is an
anti-bone resorptive agent administered to cancer patients with bone metastases at the clinical
dose of 4 mg via intravenous injection every 3–4 weeks [39]. Although treatment with clinical
doses of bisphosphonates (a daily dose 3 μg/kg or a weekly dose of 20 μg/kg) has been reported
to inhibit skeletal tumor growth in murine models [39], zoledronic acid at high doses, 0.1 or
0.125 mg/kg, was administered to exhibit its in vivo anti-tumor effect in recent studies [40–42].
In this study, zoledronic acid at 0.1 mg/kg also reduced bone metastasis and bone loss in man-
dibles, femora, and tibiae in mice with intracardiac injection of MDA-MB-23l cells. 15d-PGJ2
at 2 mg/kg showed a similar effect with zoledronic acid at 0.1 mg/kg. These results demonstrate
that administration of 15d-PGJ2 inhibits the bone metastasis of breast cancer and the resulting
bone destruction.
Currently, the main clinical drugs for the treatment of cancer-associated skeletal lesions are
inhibitors of osteoclastic bone resorption, including bisphosphonates and denosumab as a
monoclonal antibody against RANKL [43]. These agents are beneficial for the prevention and
treatment of osteoporosis in postmenopausal women [44]. In addition, bisphosphonates and
denosumab decrease estrogen deficiency-related bone loss due to aromatase inhibitor therapy
and cytotoxic chemotherapy in cancer patients [7]. We determined whether 15d-PGJ2, which
exhibits potent anti-osteoclastic and anti-bone resorptive activity, prevented bone loss in OVX
mice as a standard model for the pharmaceutical evaluation of estrogen deficiency-induced os-
teoporosis. Subcutaneously administered 15d-PGJ2 delayed weight gain and damage to femoral
trabecular bone in OVX mice, as evidenced by bone morphometric parameters, reconstructed
3D images, histological analyses, and biochemical parameters. The serum levels of the pro-in-
flammatory cytokines TNF-α and IL-1β, which are key mediators of bone loss following estro-
gen withdrawal via the promotion of osteoclastic bone resorption [45], were also reduced in
15d-PGJ2-treated OVX mice. These results indicate that 15d-PGJ2 prevents bone loss during
estrogen deficiency-inducing cancer treatment.
In summary, 15d-PGJ2 inhibited the proliferation, migration, and invasion of MDA-MB-
231 cells and the production of a major osteolytic factor, PTHrP. 15d-PGJ2 also suppressed the
RANKL/OPG ratio in osteoblastic cells exposed to breast cancer cell-derived osteolytic factors,
the RANKL-induced differentiation of osteoclast precursors, and the formation of resorbed
pits by decreasing the activities of cathepsin K and MMPs. Furthermore, subcutaneous injec-
tions of 15d-PGJ2 reduced the metastasis of breast cancer cells into bone and the generation of
osteolytic lesions in mice. Treatment with 15d-PGJ2 inhibited estrogen deficiency-induced
Fig 6. Effect of 15d-PGJ2 on ovariectomy-induced bone loss.OVXmice were subcutaneously injected
with vehicle, 15d-PGJ2, or E2 (10 μg/kg) for 10 weeks (n = 10). Sham-operated mice received vehicle alone
(n = 10). (A) Bone morphometric parameters, including BMD, BV/TV, Tb.Th, Tb.N, Th.Sp, and SMI, were
measured using μCT analysis of the femora frommice. (B) 3D images of distal femora of mice were obtained
from the reconstruction of μCT data (upper). Sagittal sections of distal femora frommice were stained with
Goldner's trichrome. Bone trabeculae appear green, and bone marrow appears red. Stained sections were
photographed using a light microscope (100x magnification). (C) Body weights of all mice were measured,
and blood sera were collected from all mice for analyses of biochemical parameters. Serum levels of calcium,
ALP, osteocalcin, TRAP, and CTX were evaluated using the respective kits as described in Materials and
Methods. (D) Serum levels of TNF-α and IL-1β were determined using specific ELISA kits. Data are
expressed as the means ± SEM. #P< 0.05, ##P< 0.01 vs. sham group. *P<0.05, **P<0.01 vs. OVX group.
doi:10.1371/journal.pone.0122764.g006
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bone loss. Therefore, 15d-PGJ2 and 15d-PGJ2-inducing agents may be potent candidates for
the prevention and treatment of bone loss caused by breast cancer bone metastasis and
chemotherapy.
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